Benitec Biopharma Inc. BNTC
Set alert
8.74 USD -0.09 -1.02%
At close · Oct 30
8.74 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
8.43 Day range 8.93
8.11 52-week range 16.36
- YTD
- -35.12%
- 1 year
- -45.95%
- Open
- 8.80
- Prev close
- 8.83
- Mkt cap
- 304.93M
- Vol
- 135.49K
- Avg vol
- 177.05K
- EPS
- -0.98
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.43
- High
- 8.93
- Forward P/E
- -1.23
- Beta
- 0.88
- Short ratio
- 1.35
- Inst. own
- 82.59%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 11, 2025
- 50-d avg
- 10.82
- 200-d avg
- 8.69
- 1y target
- 25.43
3M chart
Signals (21)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 14, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 6, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 2, 2026 | 4 weeks ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bullish | Sep 4, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 1 month ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bearish | Aug 27, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 26, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 2 months ago |
Key statistics
- Market cap
- 268.85M
- Enterprise value
- 62.15M
- Trailing P/E
- 0.00
- Forward P/E
- -1.23
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.47
- EPS (TTM)
- -2.94
- Beta
- 0.88
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -11.68M
- Total cash
- 50.87M
- Total debt
- 284.00K
- Return on equity
- -91.68%
- Shares outstanding
- 23.22M
- Short % of float
- 0.72%
- 50-day average
- 10.82
- 200-day average
- 8.69
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 25.43 +190.9% upside
Now 8.74
- Target (low)
- 17.00
- Target (mean)
- 25.43
- Target (high)
- 35.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 11, 2025
Expected Feb 11, 2025. Consensus EPS estimate -0.39.
Financials — quick view
BNTC Revenue — quarterly 0
BNTC Net income — quarterly -12.81M
BNTC EPS — quarterly -0.26
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2025 | Dec 1, 2024 | -1.00 | — | — | — |
| Nov 14, 2024 | Sep 1, 2024 | -0.61 | -0.48 | +0.13 | +21.31% |
| Sep 26, 2024 | Jun 1, 2024 | -0.58 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -1.64 | — | — |
| Feb 13, 2024 | Dec 1, 2023 | 0.00 | -2.64 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -2.76 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 13, 2024 | Baird | init | — | Outperform |
| Dec 3, 2024 | Guggenheim | reit | Buy | Buy |
| Jul 22, 2024 | Leerink Partners | init | — | Outperform |
| Jun 13, 2024 | Piper Sandler | init | — | Overweight |
| Apr 22, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Feb 15, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- benitec.com
News
- Benitec Biopharma Announces Its Interim Data From BB-301 Phase 1b/2a Trial Shows Continued Durable Enhancements In Participants Treated With Low Dose Of BB-301; 100% Response Rate Seen Across All Patients Treated
- Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301
- This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
- Raymond James Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $14
- Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17
- Benitec Biopharma Q4 EPS $(0.26), Inline
- This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
- Wedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Why Cutera Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Wednesday's Session
Your note
Sign in to keep a note on BNTC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOSTON MEGAN JOAN | Officer and Director | Purchase | Aug 10, 2023 | 25,927 |
| BUCHI J. KEVIN | Director | Purchase | Aug 10, 2023 | 52,097 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 2, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 38.03% | 8,829,053 | 102.24M | Sep 29, 2024 |
| Janus Henderson Group PLC | 3.78% | 876,523 | 10.15M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 3.62% | 841,395 | 9.74M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 3.61% | 838,095 | 9.71M | Sep 29, 2024 |
| Franklin Resources, Inc. | 3.43% | 796,644 | 9.23M | Sep 29, 2024 |
| AWM Investment Company, Inc. | 2.69% | 625,000 | 7.24M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discove | 2.47% | 573,221 | 6.64M | Jul 30, 2024 |
| Vanguard Extended Market Index Fund | 0.90% | 207,793 | 2.41M | Sep 29, 2024 |
| Simplify Exchange Traded Fds-Health Care ETF | 0.50% | 116,535 | 1.35M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.21% | 47,680 | 552.13K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.07% | 15,669 | 181.45K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 11,397 | 131.98K | Oct 30, 2024 |